Home › Compare › CSCHF vs ABBV
CSCHF yields 334.34% · ABBV yields 3.06%● Live data
📍 CSCHF pulled ahead of the other in Year 1
Combined, CSCHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSCHF + ABBV for your $10,000?
China Renaissance Holdings Limited, an investment holding company, engages in investment banking and investment management businesses in Mainland China, Hong Kong, and the United States. It operates through Investment Banking, Investment Management, CR Securities, and Others segments. The Investment Banking segment offers financial advisory, and merger and acquisition advisory services; equity underwriting, sales, trading, brokerage, and research services; and structured financing services, which include exploring and developing non-equity financing services for new-economy firms. The Investment Management segment provides fund and asset management services for individual and institutional clients, as well as manages investment in funds. The CR Securities segment offers investment banking and asset management services. The Others provides wealth management services for high-net-worth individuals and other high net worth groups, as well as invests in and manages funds. The company serves startup and high-growth China-based companies, institutional secondary equity investors, and high net-worth individuals. China Renaissance Holdings Limited was founded in 2005 and is based in Beijing, China.
Full CSCHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.